Tracy McFadden
Family · Baltimore, MDNPI 1033875414
Payments from drug & device makers
Across 36 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$142
- Neurelis, Inc.$56
- Novartis$51
- Tanabe Pharma America, Inc.$50
- CSL Behring$49
- AstraZeneca$44
- plus $406 from 16 others
What the payments were for
- Food & beverage$796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $142 |
| Neurelis, Inc. | 3 | $56 |
| Novartis | 3 | $51 |
| Tanabe Pharma America, Inc. | 2 | $50 |
| CSL Behring | 2 | $49 |
| AstraZeneca | 2 | $44 |
| Amgen | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Eisai Inc. | 2 | $35 |
| UCB, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
| Biogen | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$796 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 15 | $6,946 |
| Pregabalin | 25 | $2,988 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 14 | $1,762 |
| Gabapentin | 44 | $1,395 |
| Levetiracetam | 23 | $719 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 38 | $692 |
| Memantine Hcl | 33 | $687 |
| Primidone | 15 | $583 |
| Donepezil Hcl | 55 | $462 |
| Oxcarbazepine | 12 | $348 |
Paid to pharmacies, not to this prescriber.
Other family in Baltimore
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Lisa ScottiBaltimore$35K
- Leah HartBaltimore$32K
- Jinae ArneklevBaltimore$24K
- Valerie OwenBaltimore$12K
- Eldho ChackoBaltimore$12K
- Melonie OwusuBaltimore$10K
- Amanda NevinBaltimore$9K
- Suryamol ChackoBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.